The two companies are to draw on their experience in the life sciences field to develop an oral probiotic for the treatment of antibiotic associated diarrhoea, specifically addressing hospital infections which cause this condition. “This project would not have been possible without Enterprise Europe Scotland’s support,” said Encap’s Sales and Marketing Director Dr Robbie Stewart. “We thank them for all their help and advice so far.”
Contact between Probac and Encap was initiated via an Enterprise Europe Network partnering event. Enterprise Europe Scotland then facilitated a company meeting in Edinburgh, where negotiations began in earnest.
Dr Claire Melville, Enterprise Europe Scotland adviser commented: “Encap is a world leader in the provision of innovative solutions to drug delivery challenges. Their profiles have generated a number of excellent enquiries from our network colleagues across Europe.”
The Scottish company will develop and manufacture the probiotic product using its patented DuoCap technology. Probac will be responsible for the supply of selected microbial strains and conducting a volunteer study. The project is also supported by a Scottish Enterprise R&D grant.
“This is an exciting collaboration and initial results look extremely promising,” says Robbie. “Finding treatments for antibiotic-associated diarrhoea within the hospital is of critical importance today.”
Formed in 1989, Encap has grown into a major provider to the pharmaceutical industry. Its Scottish facility, dedicated to the development and manufacture of liquid filled hard capsules, is the largest of its type in the world. Enterprise Europe Scotland continues to support the company with partner brokerage event and technology matchmaking services.